The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1250 Weight Loss articles
Social media is buzzing with reports of hair loss among GLP-1 users on drugs like Ozempic and Wegovy. While research is emerging, experts like Yale dermatologist Dr. Sara Perkins confirm patients are noticing more shedding. Here's the science behind it and steps to address it.
North Carolina Poison Control is alerting GLP-1 users to watch for common dosing mistakes after averaging one to two calls daily last year. With 80% involving administration errors for drugs like Ozempic, Wegovy, and Mounjaro, most cases were mild but highlight real risks. Discover symptoms, prevention strategies, and FDA advice on compounded GLP-1 drugs.
Researchers from the University of Bristol and UCL have found that GLP-1 drugs like Wegovy and Ozempic could dramatically reduce the risk of 'no-reflow,' a deadly complication affecting up to half of heart attack patients. By relaxing tiny blood vessels, these medications may prevent further heart damage even if given by paramedics on-site. This study opens doors for repurposing popular obesity and diabetes treatments in emergency cardiac care.
At 92, actress Joan Collins declares she'd 'never dream' of using Ozempic, citing 'too many disastrous faces' and her aversion to needles. This sparks discussion as Kelly Osbourne confronts cruel commentary on her look at the Brit Awards. Learn the medical context behind these celebrity views on GLP-1 drugs.
Fifteen years before Ozempic sparked the GLP-1 revolution, Zydus Lifesciences in India developed ZYOG1, a promising oral GLP-1 agonist. Showing preclinical benefits for glucose control, weight loss, and a clean safety profile, it earned phase I trial approval in 2010—but was shelved amid high costs. This untold story highlights India's early edge in peptide therapy.
A Rhode Island mother battled alcoholism for years, losing custody of her son—until GLP-1 drugs like Wegovy changed everything. In a pilot program at Open Doors transitional home, Gina Roberts stopped her cravings, got sober for two years, and rebuilt her life. Addiction specialists share why these weight-loss meds show promise for addiction recovery.
Glenmark Pharmaceuticals is gearing up to launch affordable versions of semaglutide, the blockbuster GLP-1 drug for diabetes and obesity, later this month. This move intensifies competition among Indian drugmakers like Sun Pharma and Dr Reddy's following the March 21 patent expiry. With prices potentially half those of innovators, millions of patients stand to gain better access.
New research from the University of Toronto reveals that older adults with diabetes taking semaglutide (Ozempic and Wegovy) face more than double the risk of neovascular age-related macular degeneration (nAMD), a severe form of vision loss. The study, published in JAMA Ophthalmology, highlights increased risks with longer use and certain comorbidities. Patients should prioritize regular eye exams to catch issues early.
After losing insurance coverage for GLP-1 drugs like Zepbound, Massachusetts patients are grappling with $500 monthly costs or the fear of regaining lost weight. Stories from Tierno, Markert, and others highlight the struggle, as doctors warn of health risks from discontinuation. Discover the coverage changes, patient impacts, and potential paths forward.
